Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2017
At a glance
- Drugs Venglustat (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms MOVES-PD
- Sponsors Sanofi; Sanofi Genzyme
- 01 Jun 2017 Planned End Date changed from 1 Dec 2021 to 7 Apr 2022.
- 01 Jun 2017 Planned primary completion date changed from 7 Nov 2019 to 1 Mar 2021.
- 13 Mar 2017 Time frame of primary end point has been changed from baseline to Week 52 to baseline to Week 8, and at Week 52.